Jasper Therapeutics Stock (NASDAQ:JSPR)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$21.53

52W Range

$5.00 - $31.01

50D Avg

$21.32

200D Avg

$22.00

Market Cap

$323.58M

Avg Vol (3M)

$271.75K

Beta

2.20

Div Yield

-

JSPR Company Profile


Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

45

IPO Date

Jan 10, 2020

Website

JSPR Performance


JSPR Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-70.49M$-51.20M$-36.83M
Net Income$-64.47M$-24.17M$-23.98M
EBITDA$-69.38M$-64.12M$-43.11M
Basic EPS$-6.18$-0.66$-2.11
Diluted EPS$-6.18$-0.66$-2.11

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
EQEquillium, Inc.
HOOKHOOKIPA Pharma Inc.
INZYInozyme Pharma, Inc.
ORICORIC Pharmaceuticals, Inc.
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
INBXInhibrx Biosciences, Inc.
ELDNEledon Pharmaceuticals, Inc.
DSGNDesign Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
XLOXilio Therapeutics, Inc.
EPIXESSA Pharma Inc.
LYRALyra Therapeutics, Inc.